8 recherche sur le mot-clé 'Randomized controlled trials'

Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials / Han ZHU ; Jia-Qi JING ; Si-Jia JIA ; Su-Hong YU ; Chang-Jiang YANG in Research in Autism Spectrum Disorders, 114 (June 2024)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Titre : Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials Type de document : texte imprimé Auteurs : Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur Année de publication : 2024 Article en page(s) : p.102363 Langues : Anglais (eng) Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = 1.08, p = 0.008), the tablet (WMD = 2.80, p = 0.003), 3-month intervention (WMD = 2.54, p = 0.003), and the single-center studies (WMD = 2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529 [article] Can bumetanide be a miraculous medicine for autism spectrum disorder: Meta-analysis evidence from randomized controlled trials [texte imprimé] / Han ZHU, Auteur ; Jia-Qi JING, Auteur ; Si-Jia JIA, Auteur ; Su-Hong YU, Auteur ; Chang-Jiang YANG, Auteur . - 2024 . - p.102363. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 114 (June 2024) . - p.102363 Mots-clés : Bumetanide  Autism spectrum disorder  Overall core symptoms  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background The efficacy of bumetanide on autism spectrum disorders (ASD) has been extensively studied, but the results remain inconclusive, necessitating a critical examination to determine its therapeutic role. Therefore, this study conducted a meta-analysis of bumetanide treatments for ASD to explore its efficacy and identify subpopulation that responded positively. Methods A systematic search was conducted on PubMed, EMBASE, MEDLINE, PsyclNFO, Web of Science, Clinical Trials.gov, and references in reviews from the earliest available date to September 2023. Randomized controlled trials (RCTs) were identified that evaluated the efficacy of bumetanide in improving overall core symptoms (OCS) of ASD. Therefore, nine studies with 1036 participants were included in the study. Results Bumetanide showed significant effects on OCS of ASD (WMD = ? 1.91, p = 0.006), particularly in sub-domains including relation to inanimate objects, adaption to environment changes, auditory response, near sensory responses, anxiety and hyperactivity. Moderating analysis indicated that a significant effect size of bumetanide on OCS of ASD was observed in specific subgroup, including 3-6 years old (WMD = 1.08, p = 0.008), the tablet (WMD = 2.80, p = 0.003), 3-month intervention (WMD = 2.54, p = 0.003), and the single-center studies (WMD = 2.80, p = 0.003). Conclusions Bumetanide has a large and significant impact on the OCS of ASD. Given the limited number and quality of included RCTs, future research should prioritize conducting large-scale trials focusing on sub-parameters or specific clinical features to comprehensively evaluate the efficacy of bumetanide in subpopulations of children with ASD. En ligne : https://doi.org/10.1016/j.rasd.2024.102363 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=529

Genetically informed learning interventions for autism spectrum disorder: A systematic review of randomized controlled trials / Öznur Özge ÖZCAN in Research in Autism, 129 (January 2026)  

Public ISBD [article]  inResearch in Autism > 129 (January 2026) . - 202742 Titre : Genetically informed learning interventions for autism spectrum disorder: A systematic review of randomized controlled trials Type de document : texte imprimé Auteurs : Öznur Özge ÖZCAN, Auteur ; Burcu ÇEVRELI, Auteur ; Marwan Abdelmahmoud Abdelkarim MAKI, Auteur ; Palanirajan Vijayaraj KUMAR, Auteur ; Türker Tekin ERGÜZEL, Auteur Année de publication : 2026 Article en page(s) : 202742 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Genetics  Learning  Randomized controlled trials  Precision intervention  Early behavioral therapy Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder (ASD) is a genetically heterogeneous neurodevelopmental condition in which structured, learning-based interventions can promote developmental gains. However, the moderating role of genetic or ASD releated neurobiological factors in treatment responsiveness remains unclear. Methods We conducted a systematic review of randomized controlled trials (RCTs) that combined structured, learning-based interventions with either direct genetic stratification (e.g., polygenic risk scores, rare variants) or indirect neurobiological proxies (e.g., EEG, developmental profiles). The risk of bias was assessed via the Cochrane RoB 2.0 tool. Results Comprehensive database searches yielded 6565 records, of which 95 full texts were screened until June 2025. Seven RCTs met inclusion criteria. The seven trials, included a total of ∼650 participants aged 18 months to 17 years. Four studies reported significant gains in IQ, language, and adaptive behavior following early behavioral interventions (e.g., ESDM, iPad-assisted therapy, parent-mediated training). Telehealth approaches demonstrated comparable feasibility and effectiveness to in-person delivery. Two genotype-stratified RCTs provided novel evidence of biological moderation: one large-scale trial (n = 207) showed that children with rare exonic variants exhibited reduced responsiveness to social skills group training, while another (n = 188) linked higher ADHD polygenic risk scores and synaptic burden to poorer intervention outcomes. Risk of bias was generally moderate to low, and certainty of evidence ranged from moderate (small pilot studies) to high (large, multicenter RCTs). Conclusion Early structured learning interventions consistently improve developmental outcomes in children with ASD, with emerging evidence that genetic architecture may shape individual variability in treatment response. These findings highlight the need to integrate genetic and neurobiological data into future trials to advance precision education and personalized intervention strategies. En ligne : https://doi.org/10.1016/j.reia.2025.202742 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573 [article] Genetically informed learning interventions for autism spectrum disorder: A systematic review of randomized controlled trials [texte imprimé] / Öznur Özge ÖZCAN, Auteur ; Burcu ÇEVRELI, Auteur ; Marwan Abdelmahmoud Abdelkarim MAKI, Auteur ; Palanirajan Vijayaraj KUMAR, Auteur ; Türker Tekin ERGÜZEL, Auteur . - 2026 . - 202742. Langues : Anglais (eng) in Research in Autism > 129 (January 2026) . - 202742 Mots-clés : Autism spectrum disorder  Genetics  Learning  Randomized controlled trials  Precision intervention  Early behavioral therapy Index. décimale : PER Périodiques Résumé : Background Autism spectrum disorder (ASD) is a genetically heterogeneous neurodevelopmental condition in which structured, learning-based interventions can promote developmental gains. However, the moderating role of genetic or ASD releated neurobiological factors in treatment responsiveness remains unclear. Methods We conducted a systematic review of randomized controlled trials (RCTs) that combined structured, learning-based interventions with either direct genetic stratification (e.g., polygenic risk scores, rare variants) or indirect neurobiological proxies (e.g., EEG, developmental profiles). The risk of bias was assessed via the Cochrane RoB 2.0 tool. Results Comprehensive database searches yielded 6565 records, of which 95 full texts were screened until June 2025. Seven RCTs met inclusion criteria. The seven trials, included a total of ∼650 participants aged 18 months to 17 years. Four studies reported significant gains in IQ, language, and adaptive behavior following early behavioral interventions (e.g., ESDM, iPad-assisted therapy, parent-mediated training). Telehealth approaches demonstrated comparable feasibility and effectiveness to in-person delivery. Two genotype-stratified RCTs provided novel evidence of biological moderation: one large-scale trial (n = 207) showed that children with rare exonic variants exhibited reduced responsiveness to social skills group training, while another (n = 188) linked higher ADHD polygenic risk scores and synaptic burden to poorer intervention outcomes. Risk of bias was generally moderate to low, and certainty of evidence ranged from moderate (small pilot studies) to high (large, multicenter RCTs). Conclusion Early structured learning interventions consistently improve developmental outcomes in children with ASD, with emerging evidence that genetic architecture may shape individual variability in treatment response. These findings highlight the need to integrate genetic and neurobiological data into future trials to advance precision education and personalized intervention strategies. En ligne : https://doi.org/10.1016/j.reia.2025.202742 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=573

Goal Attainment Scaling as an Outcome Measure in Randomized Controlled Trials of Psychosocial Interventions in Autism / Lisa A. RUBLE in Journal of Autism and Developmental Disorders, 42-9 (September 2012)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 42-9 (September 2012) . - p.1974-1983 Titre : Goal Attainment Scaling as an Outcome Measure in Randomized Controlled Trials of Psychosocial Interventions in Autism Type de document : texte imprimé Auteurs : Lisa A. RUBLE, Auteur ; John H. MCGREW, Auteur ; Michael D. TOLAND, Auteur Année de publication : 2012 Article en page(s) : p.1974-1983 Langues : Anglais (eng) Mots-clés : Goal attainment scaling  Outcome measurement  Autism  Randomized controlled trials  Reliability  Psychosocial intervention Index. décimale : PER Périodiques Résumé : Goal attainment scaling (GAS) holds promise as an idiographic approach for measuring outcomes of psychosocial interventions in community settings. GAS has been criticized for untested assumptions of scaling level (i.e., interval or ordinal), inter-individual equivalence and comparability, and reliability of coding across different behavioral observation methods. We tested assumptions of equality between GAS descriptions for outcome measurement in a randomized trial (i.e., measurability, equidistance, level of difficulty, comparability of behavior samples collected from teachers vs. researchers and live vs. videotape). Results suggest GAS descriptions can be evaluated for equivalency, that teacher collected behavior samples are representative, and that varied sources of behavior samples can be reliably coded. GAS is a promising measurement approach. Recommendations are provided to ensure methodological quality. En ligne : http://dx.doi.org/10.1007/s10803-012-1446-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=180 [article] Goal Attainment Scaling as an Outcome Measure in Randomized Controlled Trials of Psychosocial Interventions in Autism [texte imprimé] / Lisa A. RUBLE, Auteur ; John H. MCGREW, Auteur ; Michael D. TOLAND, Auteur . - 2012 . - p.1974-1983. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 42-9 (September 2012) . - p.1974-1983 Mots-clés : Goal attainment scaling  Outcome measurement  Autism  Randomized controlled trials  Reliability  Psychosocial intervention Index. décimale : PER Périodiques Résumé : Goal attainment scaling (GAS) holds promise as an idiographic approach for measuring outcomes of psychosocial interventions in community settings. GAS has been criticized for untested assumptions of scaling level (i.e., interval or ordinal), inter-individual equivalence and comparability, and reliability of coding across different behavioral observation methods. We tested assumptions of equality between GAS descriptions for outcome measurement in a randomized trial (i.e., measurability, equidistance, level of difficulty, comparability of behavior samples collected from teachers vs. researchers and live vs. videotape). Results suggest GAS descriptions can be evaluated for equivalency, that teacher collected behavior samples are representative, and that varied sources of behavior samples can be reliably coded. GAS is a promising measurement approach. Recommendations are provided to ensure methodological quality. En ligne : http://dx.doi.org/10.1007/s10803-012-1446-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=180

Occupational therapy in Autism Spectrum Disorder: A scoping umbrella review of randomized controlled trials / Marta MARCILLA-JORDÁ in Research in Autism, 132 (April 2026)  

Public ISBD [article]  inResearch in Autism > 132 (April 2026) . - 202866 Titre : Occupational therapy in Autism Spectrum Disorder: A scoping umbrella review of randomized controlled trials Type de document : texte imprimé Auteurs : Marta MARCILLA-JORDÁ, Auteur ; Susana MONTAÑES-MARTÍ, Auteur ; César RUBIO-BELMONTE, Auteur ; Micaela MORO-IPOLA, Auteur Article en page(s) : 202866 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder  Occupational Therapy  Systematic Review  Randomized Controlled Trials  Outcome Measures  Assessment Résumé : Introduction The rising prevalence of Autism Spectrum Disorder (ASD) highlights the need for effective interventions. Occupational therapists (OTs) are increasingly called upon to provide assessments and interventions for individuals with ASD. While many systematic reviews (SRs) have explored evidence-based OT interventions for ASD, there is a gap in the literature regarding the methodological quality of SRs, the outcome measures used in their included studies, and the degree of involvement of OT in the associated randomized controlled trials (RCTs). To address this, a scoping umbrella review of RCTs was developed. Methods The review adhered to PRISMA guidelines and was registered in PROSPERO (CRD42023387068). A search for SRs on OT and children/ youth with ASD was performed (October-November 2024). SRs quality was assessed using AMSTAR-2 tool and RCTs were extracted from the SRs. Results Ten SRs met the inclusion criteria, from which 43 RCTs were extracted and analysed. The most frequent professional profile in RCTs was "undefined profile" (54.5 %) and a total of 109 distinct assessment tools were identified. The three most frequently used outcome measures were the Vineland Adaptive Behaviour Scales, the Autism Diagnostic Observation Schedule, and the Social Responsiveness Scale-2. Conclusion Findings reveal a need for high-quality OT research and a lack of RCTs where OTs play a leading role. Furthermore, while the three aforementioned tools are indispensable for diagnosis, their original purpose was not to measure intervention effectiveness. To conduct a quality assessment in ASD, assessment tools that can measure functionality and are sensitive to changes in symptomatology are needed. En ligne : https://doi.org/10.1016/j.reia.2026.202866 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=583 [article] Occupational therapy in Autism Spectrum Disorder: A scoping umbrella review of randomized controlled trials [texte imprimé] / Marta MARCILLA-JORDÁ, Auteur ; Susana MONTAÑES-MARTÍ, Auteur ; César RUBIO-BELMONTE, Auteur ; Micaela MORO-IPOLA, Auteur . - 202866. Langues : Anglais (eng) in Research in Autism > 132 (April 2026) . - 202866 Mots-clés : Autism Spectrum Disorder  Occupational Therapy  Systematic Review  Randomized Controlled Trials  Outcome Measures  Assessment Résumé : Introduction The rising prevalence of Autism Spectrum Disorder (ASD) highlights the need for effective interventions. Occupational therapists (OTs) are increasingly called upon to provide assessments and interventions for individuals with ASD. While many systematic reviews (SRs) have explored evidence-based OT interventions for ASD, there is a gap in the literature regarding the methodological quality of SRs, the outcome measures used in their included studies, and the degree of involvement of OT in the associated randomized controlled trials (RCTs). To address this, a scoping umbrella review of RCTs was developed. Methods The review adhered to PRISMA guidelines and was registered in PROSPERO (CRD42023387068). A search for SRs on OT and children/ youth with ASD was performed (October-November 2024). SRs quality was assessed using AMSTAR-2 tool and RCTs were extracted from the SRs. Results Ten SRs met the inclusion criteria, from which 43 RCTs were extracted and analysed. The most frequent professional profile in RCTs was "undefined profile" (54.5 %) and a total of 109 distinct assessment tools were identified. The three most frequently used outcome measures were the Vineland Adaptive Behaviour Scales, the Autism Diagnostic Observation Schedule, and the Social Responsiveness Scale-2. Conclusion Findings reveal a need for high-quality OT research and a lack of RCTs where OTs play a leading role. Furthermore, while the three aforementioned tools are indispensable for diagnosis, their original purpose was not to measure intervention effectiveness. To conduct a quality assessment in ASD, assessment tools that can measure functionality and are sensitive to changes in symptomatology are needed. En ligne : https://doi.org/10.1016/j.reia.2026.202866 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=583

Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials / Yue WANG in Research in Autism Spectrum Disorders, 64 (August 2019)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 64 (August 2019) . - p.63-75 Titre : Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials Type de document : texte imprimé Auteurs : Yue WANG, Auteur ; Meng-Jie WANG, Auteur ; Ying RONG, Auteur ; Hui-Zhong HE, Auteur ; Chang-Jiang YANG, Auteur Article en page(s) : p.63-75 Langues : Anglais (eng) Mots-clés : Oxytocin  Autism spectrum disorder  Social function  Repetitive behaviors  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background Evidence of oxytocin for treating core symptoms in autism spectrum disorder (ASD) across development remains mixed and establishing its role is critical for guiding therapy. Aim The current paper is aimed to include new studies and provide a stricter and updated meta-analysis to assess the oxytocin's effects on core symptoms in ASD. Method Computerized search was conducted in PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science Database and references in reviews from the earliest date available to September 2018. Randomized controlled trials (RCTs) were identified which evaluated the effectiveness of oxytocin on at least one of two domains in patients with ASD, namely social function and repetitive behaviors. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I2 test. Results Sixteen studies comprising 520 individuals with ASD were included in this meta-analysis. Results suggested that oxytocin had a small and non-significant effect on social function [SMD = 0.03, 95% CI (−0.19, 0.25), p = 0.781] and repetitive behaviors [SMD = 0.01, 95% CI (−0.26, 0.27), p = 0.952] compared with placebo. Studies included had a low heterogeneity (I2 = 46.4%, p = 0.025 in social function; I2 = 37.0%, p = 0.123 in repetitive behaviors). Conclusions The current meta-analysis demonstrated that oxytocin had a small and non-significant effect on core symptoms in ASD population. With the limited number of included studies, more large-scale, rigorously and multi-site RCTs are needed to confirm the effectiveness of oxytocin as a treatment of ASD to acquire more convincing conclusions in the future. En ligne : https://doi.org/10.1016/j.rasd.2019.03.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399 [article] Oxytocin therapy for core symptoms in autism spectrum disorder: An updated meta-analysis of randomized controlled trials [texte imprimé] / Yue WANG, Auteur ; Meng-Jie WANG, Auteur ; Ying RONG, Auteur ; Hui-Zhong HE, Auteur ; Chang-Jiang YANG, Auteur . - p.63-75. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 64 (August 2019) . - p.63-75 Mots-clés : Oxytocin  Autism spectrum disorder  Social function  Repetitive behaviors  Meta-analysis  Randomized controlled trials Index. décimale : PER Périodiques Résumé : Background Evidence of oxytocin for treating core symptoms in autism spectrum disorder (ASD) across development remains mixed and establishing its role is critical for guiding therapy. Aim The current paper is aimed to include new studies and provide a stricter and updated meta-analysis to assess the oxytocin's effects on core symptoms in ASD. Method Computerized search was conducted in PubMed, EMBASE, Cochrane Library, PsycINFO, Web of Science Database and references in reviews from the earliest date available to September 2018. Randomized controlled trials (RCTs) were identified which evaluated the effectiveness of oxytocin on at least one of two domains in patients with ASD, namely social function and repetitive behaviors. Standardized mean difference (SMD) and 95% confidence intervals (CIs) were calculated, and heterogeneity was assessed using the I2 test. Results Sixteen studies comprising 520 individuals with ASD were included in this meta-analysis. Results suggested that oxytocin had a small and non-significant effect on social function [SMD = 0.03, 95% CI (−0.19, 0.25), p = 0.781] and repetitive behaviors [SMD = 0.01, 95% CI (−0.26, 0.27), p = 0.952] compared with placebo. Studies included had a low heterogeneity (I2 = 46.4%, p = 0.025 in social function; I2 = 37.0%, p = 0.123 in repetitive behaviors). Conclusions The current meta-analysis demonstrated that oxytocin had a small and non-significant effect on core symptoms in ASD population. With the limited number of included studies, more large-scale, rigorously and multi-site RCTs are needed to confirm the effectiveness of oxytocin as a treatment of ASD to acquire more convincing conclusions in the future. En ligne : https://doi.org/10.1016/j.rasd.2019.03.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=399

Screening, Intervention and Outcome in Autism and Other Developmental Disorders: The Role of Randomized Controlled Trials / Elisabeth FERNELL in Journal of Autism and Developmental Disorders, 44-8 (August 2014)  

Permalink

Four-year follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder / Jeffrey R. WOZNIAK in Journal of Neurodevelopmental Disorders, 12 (2020)  

Permalink

Can technology-based interventions be an alternative method for emotion recognition in autism spectrum disorder: Three-level meta-analysis insights from RCTs / Hong-Li XIAO in Research in Autism, 133 (May 2026)  

Permalink